Advisory Committee Meeting | In Person
Event Title
May 9, 2017: Science Board to the Food and Drug Administration Meeting Announcement
May 8, 2017
- Date:
- May 9, 2017
What is an advisory committee?
Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.
| Center | Date | Time | Location |
|---|---|---|---|
| OC | May 9, 2017 | 2:00 p.m. - 5:00 p.m. | FDA White Oak Campus |
This meeting will take place via audio webcast.
Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at Common Questions and Answers About FDA Advisory Committee Meetings.
For those unable to access the audio webcast, a conference room with a speakerphone will be reserved at the meeting location provided at the top of this page in the Location section. Seating is limited and is available on a first come, first served basis.
Agenda
The Science Board will provide recommendations on the Agency’s Innovation Funds work plan as prescribed in section 1002 of the 21st Century Cures Act (Pub. L. 114-255).
Meeting Materials
FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting.
Background Materials
Public Participation
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.
- Written submissions may be made to the contact person on or before May 2, 2017.
- Oral presentations from the public will be scheduled between approximately 4 p.m. and 5 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before April 24, 2017.
Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by April 25, 2017.
Contact Information
Rakesh Raghuwanshi
Office of the Chief Scientist
Office of the Commissioner
Food and Drug Administration
10903 New Hampshire Ave, Bldg. 1, rm. 3309
Silver Spring MD 20993
301-796-4769
rakesh.raghuwanshi@fda.hhs.gov
A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Advisory Committees Web page and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.
- FDA Advisory Committee Information Line
1-800-741-8138 (301-443-0572 in the Washington, DC area).
Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Rakesh Raghuwanshi at (301) 796-4769 at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website for procedures on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).
A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.
Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.
Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.
FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).